Literature DB >> 28628914

Efficacy and Safety of Tadalafil Once-a-Day versus Tadalafil On-Demand in Patients with Erectile Dysfunction: A Systematic Review and Meta-Analyses.

Zhufeng Peng1, Lu Yang, Qiang Dong, Qiang Wei, Liangren Liu, Bo Yang.   

Abstract

INTRODUCTION: To compare the efficacy and safety between tadalafil once-a-day and tadalafil on-demand dosing regimen in patients with ED.
MATERIALS AND METHODS: A systematic search of Medline, Embase, and Cochrane Library was performed to identify all randomized controlled trials (RCTs) that compared tadalafil used a once-a-day with an on-demand dosing regimen for erectile dysfunction. A secondary hand-search was performed in relevant journals, references, and the grey literature. Meta-analyses were performed using Review Manager version 5.3.0.
RESULTS: Six RCTs involving a total of 1,534 patients were included in this review. All studies reported the International Index of Erectile Function-Erectile Function domain score and the results of the meta-analysis showed no difference between the groups. The overall pooled estimated weighted mean differences (WMD) was 0.97 (95% CI -0.37 to 2.32; p = 0.16). Meta-analyses of Sexual Encounter Profile questions 2 and 3 (SEP-2 and SEP-3) showed that the once-a-day dosing regimen was superior to the on-demand regimen with statistical significance. The WMD of SEP-2 and SEP-3 were 10.32 (95% CI 3.16-17.48; p = 0.005) and 11.07 (95% CI 2.57-19.56; p = 0.01), respectively. Both dosing regimens of tadalafil showed similar complication rates. The meta-analyses of adverse events showed no significant differences.
CONCLUSIONS: The efficacy rates of tadalafil once-a-day and on-demand were similar. No significant difference in safety was found between the 2 dose regimens of tadalafil.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Dosing regimen; Erectile dysfunction; Systematic review; Tadalafil

Mesh:

Substances:

Year:  2017        PMID: 28628914     DOI: 10.1159/000477496

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

1.  Canadian Urological Association guideline: Erectile dysfunction.

Authors:  Trustin Domes; Borna Tadayon Najafabadi; Matthew Roberts; Jeffrey Campbell; Ryan Flannigan; Phil Bach; Premal Patel; Gavin Langille; Yonah Krakowsky; Philippe D Violette
Journal:  Can Urol Assoc J       Date:  2021-10       Impact factor: 1.862

2.  Diketopiperazine-Based, Flexible Tadalafil Analogues: Synthesis, Crystal Structures and Biological Activity Profile.

Authors:  Adam Mieczkowski; Elżbieta Speina; Damian Trzybiński; Maria Winiewska-Szajewska; Patrycja Wińska; Ewelina M Borsuk; Małgorzata Podsiadła-Białoskórska; Tomasz Przygodzki; Krzysztof Drabikowski; Lidia Stanczyk; Igor Zhukov; Cezary Watala; Krzysztof Woźniak
Journal:  Molecules       Date:  2021-02-03       Impact factor: 4.411

Review 3.  Cyclic Dipeptides: The Biological and Structural Landscape with Special Focus on the Anti-Cancer Proline-Based Scaffold.

Authors:  Joanna Bojarska; Adam Mieczkowski; Zyta M Ziora; Mariusz Skwarczynski; Istvan Toth; Ahmed O Shalash; Keykavous Parang; Shaima A El-Mowafi; Eman H M Mohammed; Sherif Elnagdy; Maha AlKhazindar; Wojciech M Wolf
Journal:  Biomolecules       Date:  2021-10-14

4.  Efficacy of tadalafil on improvement of men with erectile dysfunction caused by COVID-19: A randomized placebo-controlled trial.

Authors:  Iman Shamohammadi; Seyedmohammad Kazemeyni; Mohammadali Sadighi; Tara Hasanzadeh; Alireza Dizavi
Journal:  Asian J Urol       Date:  2022-08-13

Review 5.  Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?

Authors:  Geoffrey Hackett
Journal:  World J Mens Health       Date:  2020-03-26       Impact factor: 5.400

Review 6.  Novel Emerging Therapies for Erectile Dysfunction.

Authors:  Soyeun Kim; Min Chul Cho; Sung Yong Cho; Hong Chung; Mahadevan Raj Rajasekaran
Journal:  World J Mens Health       Date:  2020-03-16       Impact factor: 5.400

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.